Pulse Biosciences (NASDAQ:PLSE) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Pulse Biosciences (NASDAQ:PLSE) from a hold rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.

A number of other equities research analysts have also recently issued reports on PLSE. BTIG Research initiated coverage on Pulse Biosciences in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 price objective on the stock. Freedom Capital upgraded shares of Pulse Biosciences to a “strong-buy” rating in a research report on Wednesday, September 9th. Canaccord Genuity Group lifted their target price on shares of Pulse Biosciences from $58.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday. Mizuho set a $65.00 target price on shares of Pulse Biosciences in a research note on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $66.60.

Pulse Biosciences Price Performance

NASDAQ:PLSE opened at $53.29 on Friday. The company has a market capitalization of $3.77 billion, a P/E ratio of -44.04 and a beta of 1.65. The business has a fifty day simple moving average of $51.55 and a two-hundred day simple moving average of $32.28. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $58.90.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.52 million. Pulse Biosciences had a negative net margin of 5,603.88% and a negative return on equity of 101.91%. The firm’s quarterly revenue was down 54.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.29) EPS. As a group, analysts anticipate that Pulse Biosciences will post -1.34 earnings per share for the current year.

Insider Transactions at Pulse Biosciences

In related news, COO Liane Teplitsky acquired 1,001 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were acquired at an average price of $49.95 per share, with a total value of $49,999.95. Following the acquisition, the chief operating officer owned 4,095 shares of the company’s stock, valued at approximately $204,545.25. This trade represents a 32.35% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders bought 4,095 shares of company stock worth $199,931. Corporate insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Large investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Pulse Biosciences in the second quarter worth approximately $40,672,000. Bank of America Corp DE bought a new stake in Pulse Biosciences during the second quarter valued at approximately $40,115,000. Panoramic Capital LLC bought a new stake in Pulse Biosciences during the second quarter valued at approximately $2,719,000. Bank of New York Mellon Corp purchased a new position in Pulse Biosciences in the 2nd quarter worth approximately $1,196,000. Finally, Formula Growth Ltd. purchased a new position in Pulse Biosciences in the 2nd quarter worth approximately $832,000. 76.95% of the stock is currently owned by institutional investors.

Key Stories Impacting Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
• Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
• Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
• Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
• Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.